Aurora, CO 的 肺癌 臨床試驗
19 項針對 肺癌 的研究正在 Aurora（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Rocky Mountain Cancer Centers-Aurora, Aurora
- UCHealth University of Colorado Hospital, Aurora
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
招募中3 期
- Rocky Mountain Cancer Centers-Aurora, Aurora
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- University of Colorado Cancer Center, Aurora
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- University of Colorado - Aurora Cancer Center, Aurora
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
招募中1 期
- University of Colorado Health Hospital, Aurora
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
招募中1 期
- University of Colorado Cancer Center, Aurora
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
招募中3 期
- University of Colorado Health, Aurora
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
招募中3 期
- University of Colorado Hospital, Aurora
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
招募中3 期
- UCHealth University of Colorado Hospital, Aurora
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- UCHealth University of Colorado Hospital, Aurora
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- UCHealth University of Colorado Hospital, Aurora
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
招募中1/2 期
- University of Colorado Cancer Center, Aurora
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
招募中觀察性研究
- University of Colorado Cancer Center, Aurora
Improving Care for Rural Patients With Solid Tumors
招募中
- University of Colorado Hospital, Aurora
Specimen Banking From Patients With Lung Cancer
招募中觀察性研究
- University of Colorado Cancer Center, Aurora
Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer
招募中
- Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Aurora
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
招募中觀察性研究
- University of Colorado Cancer Center at UC Health Sciences Center, Aurora
其他城市的 肺癌 試驗
- Houston, TX78 項研究
- Boston, MA62 項研究
- New York City, NY60 項研究
- Los Angeles, CA45 項研究
- Arlington, VA41 項研究
- Washington, DC41 項研究
- Chicago, IL41 項研究
- Baltimore, MD40 項研究
- Nashville, TN40 項研究
- St. Louis, MO39 項研究
- Columbus, OH37 項研究
- Philadelphia, PA36 項研究
Aurora 的其他研究
- 癌症（所有類型）35 項研究
- 大腸直腸癌32 項研究
- 非小細胞肺癌31 項研究
- 乳癌28 項研究
- 卵巢癌25 項研究
- 轉移性癌症25 項研究
- 第一型糖尿病23 項研究
- 肥胖症22 項研究
- 前列腺癌19 項研究
- 心臟衰竭18 項研究
- 黑色素瘤18 項研究
- 急性髓系白血病16 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。